Vaccines, Vaccine Delivery Systems and Immunotherapeutics

Atherosclerosis (CETi-1) Vaccine:
Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. (2003)The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 169(1): 113-20.

Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US. (2000) Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2000 20(9):2106-12.

Herrera. V.L.M., Makrides, S.C., Xie, H.X., Adari, H., Kraus, R.M., Ryan, U.S., and Ruiz-Opazo, N. (1999) Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nature Med. 5, 383-1389.

Rotavirus Vaccine
Bernstein, D.I., Sack, D.A., Rothstein, E., Reisinger, K. Smith, V.E., O'Sullivan, D., Spriggs, D.R., Ward, R.L. (1999) Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 354, 287-290.

HIV - Therapore® Vaccine:
Lu Y., Friedman R., Kushner N., Doling A., Thomas L., Touzjian N., Starnbeach M., and Lieberman J. (2000) Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc. Natl. Acad. Sci. U.S.A. 97(14): 8027-8032.

Bacterial Vaccines and Vectors

Sizemore DR, Warner B, Lawrence J, Jones A, Killeen KP (2006). Live, Attenuated Salmonella typhimurium Vectoring Campylobacter antigens.Vaccines. 24(18):3793-803.

Sizemore DR, Roland KL, Ryan US (2004). Enterotoxigenic Escherichia coli virulence factors and vaccine approaches. Expert Rev Vaccines. 3(5):585-95.

Kochi, S.K., Killeen, K.P. & Ryan, U.S. Advances in the Development of Bacterial Vector Technology (Editorial). Expert Rev. Vaccines. 2(1), 31-43 (2003)

Killeen, K.P. & DiRita, V.J. (2001). Live Attenuated Bacterial Vaccines. In Ellis, R. ed., New Vaccine Technologies. Eurekah.com / Landes Bioscience, Georgetown, Texas.

Kochi, S.K. & Killeen, K.P. (2001) Live Attenuated Bacterial Vectors. In Ellis, R. ed., New Vaccine Technologies. Eurekah.com / Landes Bioscience, Georgetown, Texas.

Ryan ET, Crean TI, Kochi SK, John M, Luciano AA, Killeen KP, Klose KE, Calderwood SB. (2000) Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun. 68(1):221-6.

Killeen, K.P., Spriggs, D.R., and J.J. Mekalanos. (1999). Bacterial Vaccines Chapter. In Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines. Current Topics in Microbiology and Immunology. Springer-Verlag Press, Berlin, Heidelberg, New York, Tokyo.

Cholera Vaccine
Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Tareque AA, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA and the PXV study group (2007). Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 25(2):231-8.

Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA (2005). Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis. 192(4):573-9.

Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, Wowk S, Hawkins J, Kochi SK, Schiff G, Killeen KP. (2002) Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun. 2002 Apr;70(4):1965-70.

Ryan ET, Crean TI, Kochi S, John M, Luciano AA, Killeen KP, Klose KE, Calderwood SB (2000). Development of a Delta glnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun. 68(1):221-6.

Sack DA, Sack RB, Shimko J, Gomes G, O'Sullivan D, Metcalfe K, Spriggs D. (1997) Evaluation of Peru-15, a New Live Oral Vaccine for Cholera, in Volunteers. J Infect Dis. 1997:176:201-5.

Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN. (1995) Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype. Lancet 1995; 345:949-52.

Typhoid Fever Vaccine
Roland KL, Tinge SA, Killeen KP, Kochi SK (2005). Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther . 7(1):62-72.

DiPetrillo, M.D., Tibbets, T., Kleanthous, H., Killeen, K.P., and E.L. Hohmann. (1999). Safety and immunogenicity of phoP/phoQ deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 18:449-459.

Killeen, K.P., Spriggs, D.R., and J.J. Mekalanos. (1999). Bacterial Vaccines Chapter. In Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines. Current Topics in Microbiology and Immunology. Springer-Verlag Press, Berlin, Heidelberg, New York, Tokyo.

Hohmann, E.L., Oletta, C.A., Killeen, K.P. and S.I. Miller. (1996). phoP/phoQ-Deleted Salmonella typhi (Ty800) Is a Safe and Immunogenc Single-Dose Typhoid Vaccine in Volunteers. J Infect Dis. 1996:173:1408-14.

Complement Inhibitors

Soluble Complement Receptor-1 (TP10)
Zimmerman, J.L., Dellinger R.P., Straube, R.C. and Levin, J.L. (2000) Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med. 28, 3149-54.

Chai, P.J., Nassar, R., Oakeley, A.E., Craig, D.M., Quick, G. Jr., Jaggers, J., Sanders, S.P., Ungerleider, R.M. and Anderson, P.A. (2000) Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 101, 541-6.

Lazar, H.L., Bao, Y., Gaudiani, J., Rivers, S. and Marsh, H. (1999) Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 100, 1438-42.

Soluble Complement Receptor-1 sLex (TP20)
Rittershaus, C.W., Thomas, L.J., Miller, D.P., Picard, M.D.,Geoghegan-Barek, K.M., Scesney, S.M., Henry, L.D., Sen, A.S., Bertino, A.M., Hannig, G., Adari, H., Mealey, R.A., Gosselin, M.L., Couto, M., Hayman, E.G., Levin, J.L., Reinhold, V.N. and Marsh, H.C. (1999) Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274, 11237-11244.

Mulligan, M.S., Warner, R.L., Rittershaus, C.W., Thomas, L.J., Ryan, U.S., Foreman, K.E., Crouch, L.D., Till, G.O. and Ward, P.A. (1999) Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J. Immunol. 162, 4952-4959.

Huang, J., Kim, L.J., Mealey, R., Marsh, H.C. , Zhang, Y., Tenner, A.J., Connolly, E.S. and Pinsky, D.J. (1999) Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285, 595-599.